COMP <GO>
MDLN vs BDX // EV/EBITDA & P/E VALUATION
Medline Inc. (NASDAQ) VS. Becton Dickinson and Company (NYSE) • 15-METRIC TALLY: MDLN 7
— BDX 5
▲ EV/EBITDA & P/E VALUATION LEADER: MDLN
LAST: $32.12 (+0.38%) • MKT CAP: $42.07B
valuation
20.3x
LAST: $197.88 (-0.23%) • MKT CAP: $54.03B
valuation
21.8x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MDLN VS. BDX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MDLN | BDX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 45.40% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 8.20% | 4.90% | +3.30 | MDLN | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 20.3x | 21.8x | -1.50 | MDLN | /valuation <GO> |
| Free Cash Flow Yield | 3.08% | 2.13% | +0.95 | MDLN | /fcf-yield <GO> |
| Operating Margin | 7.80% | 11.80% | -4.00 | BDX | /operating-margins <GO> |
| Net Profit Margin | 68.00% | 7.70% | +60.30 | MDLN | /net-margins <GO> |
| Revenue Growth (YoY) | 11.50% | 8.20% | +3.30 | MDLN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.21% | -2.21 | BDX | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.50 | 2.22 | +0.28 | MDLN | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 8/9 | -3.00 | BDX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 30.9 | 64.6 | -33.70 | BDX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.11 | 1.06 | +0.05 | MDLN | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 29.9x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $42.07B | $54.03B | -$11.95B | BDX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MDLN REV | BDX REV | MDLN GROSS % | BDX GROSS % | MDLN FCF | BDX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $28.43B | $21.84B | 26.4% | 45.4% | $1.30B | — |
| FY 2024 | $25.51B | $20.18B | 27.3% | 45.2% | $1.42B | — |
| FY 2023 | $23.23B | $19.37B | — | — | $639.6M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MDLN // BETA 1.11
BDX // BETA 1.06